Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug–Drug Interaction with Rifampin and Liver Impairment

Cabozantinib (CAB) is a receptor tyrosine kinase inhibitor approved for the treatment of several cancer types. Enterohepatic recirculation (EHC) of the substance is assumed but has not been further investigated yet. CAB is mainly metabolized via CYP3A4 and is susceptible for drug–drug interactions (...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerner, Bettina, Scherf-Clavel, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224782/
https://www.ncbi.nlm.nih.gov/pubmed/34067429
http://dx.doi.org/10.3390/pharmaceutics13060778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224782/
https://www.ncbi.nlm.nih.gov/pubmed/34067429
http://dx.doi.org/10.3390/pharmaceutics13060778

Ejemplares similares